A Cohort Study Comparing Pediatric Patients with Overweight and Obesity in the Military Health System

Dimas C Espinola1,2, Cara Olsen1, Amanda Banaag1,3

  • 1Department of Preventive Medicine and Biostatistics, Uniformed Services University of Health Sciences, Bethesda, MD, USA.

Insights

Pediatric obesity is rising in the Military Health System (MHS), mirroring civilian trends. This increase impacts future military readiness due to weight standards eligibility.

Area of Science:

  • Pediatric Health
  • Public Health
  • Military Medicine

Background:

  • Pediatric obesity rates have been increasing nationally since the 1960s.
  • The Military Health System (MHS) sought to evaluate pediatric obesity trends within its population.
  • Understanding these trends is crucial for future military readiness.

Purpose of the Study:

  • To assess trends in Body Mass Index (BMI) categorization among pediatric patients in the MHS from 2009 to 2016.
  • To compare MHS pediatric obesity trends with civilian population data.
  • To identify implications for military service eligibility.

Main Methods:

  • Utilized MHS Data Repository for two pediatric cohorts (2009-2016).
  • Calculated BMI percentiles and z-scores using validated growth charts, removing implausible data.
  • Employed the Stuart-Maxwell test to assess changes in BMI categorization by age group.

Main Results:

  • A cohort of 130,675 pediatric patients was analyzed.
  • Significant shifts in BMI categorization occurred across all age groups (p < 0.001).
  • Increases in overweight and obesity were observed in all pediatric age groups, with shifts from healthy weight categories.

Conclusions:

  • A significant rise in pediatric overweight and obesity was observed in the MHS cohort.
  • Obesity prevalence in the MHS cohort mirrored civilian population trends.
  • Increasing childhood obesity poses a challenge to future military recruitment due to stringent weight standards.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
43
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
849
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
39
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
62
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
35
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49